Cytomegalovirus Shedding in Healthy Seropositive Female College Students: A 6-Month Longitudinal Study.

Background: Cytomegalovirus (CMV) establishes a lifelong latent infection after primary infection and may reactivate periodically, with the shedding of infectious virus in body fluids. To better understand the prevalence and shedding model of CMV in immunocompetent seropositive women of childbearing age, a 6-month longitudinal study was conducted in healthy female college students. Methods: A total of 102 nonpregnant female college students aged 18-30 years were enrolled and followed up every 2 weeks for 6 months. Saliva and urine samples were collected at each visit. Serum samples were collected at the first and last visits. Results: All participants were positive for anti-CMV immunoglobulin G (IgG) at entry. During the 6-month period, 29.4% of participants (30 of 102) shed CMV intermittently in saliva or urine. At each visit, the CMV shedding prevalence varied from 2.0% to 10.4% and presented only in 1 bodily fluid. The viral load was low and did not induce marked antibody increases. The baseline anti-CMV IgG level was not found to be associated with viral shedding. Conclusions: CMV shedding in saliva and urine is common and intermittent and does not stimulate an anamnestic antibody response in seropositive immunocompetent women of childbearing age with a low risk of exposure to exogenous infectious sources.

Specific primer amplification of the VP1 region directed by 5' UTR sequence analysis: enterovirus testing and identification in clinical samples from hand-foot-and-mouth disease patients.

Many genotypes of the enterovirus (EV) pathogens can cause clinical hand-foot-and-mouth disease (HFMD). Therefore, rapid identification and monitoring of HFMD pathogens can be difficult, especially from the original clinical specimens. In this study, both universal pan-enterovirus and EV71/CA16 VP1-specific primer sets were designed and used to examine clinical specimens from HFMD patients. Based on the initial sequence analysis of the 5'-untanslated region (5'-UTR) and VP1 amplification products, additional primers for the VP1 region were redesigned for further genotyping of the remaining small portion non-EV71/non-CA16 specimens. With a known panel, it was possible to identify 15 out of 16 members using 5'-UTR sequence typing and VP1 typing, suggesting good detectability and genotyping of this method. One strain that was not typed by 5'-UTR was shown to be a recombinant virus. When this method was applied to examine clinical specimens from 44 suspected HFMD patients, 41 were detected as EV positive. In only one case, the VP1 sequence could not be identified. Four types of EVs, including CA16 (26/41, 63.4%), EV71-C4 (6/41, 14.6%), CA6 (5/41, 12.2%) and CA10 (3/41, 7.3%), were detected. In conclusion, 5' UTR amplification sequencing and subsequent VP1 specific primer amplification ensures a high detection rate and good genotyping accuracy in the examination of clinical samples. This detection strategy can be used for routine evaluation and monitoring of HFMD to follow local trends of EV infection.